This month, we’re recognizing Sickle Cell Awareness Month and the importance of understanding fetal risk earlier in pregnancy. We’re also sharing the recording of our recent Unity Confirm provider roundtable, where prenatal care providers discussed their real-world experiences navigating care after a high-risk Unity Aneuploidy NIPT screening result.
Plus, see where you can connect with the BillionToOne team at upcoming events this October.
Sickle Cell Awareness Month: Earlier Insight Can Make a Difference
Sickle cell disease is one of the most common genetic disorders worldwide, affecting millions of people across many populations.
BillionToOne began with a goal of helping families better understand fetal risk for conditions like sickle cell disease earlier in pregnancy, a mission that continues to shape Unity today.
As care and treatment options evolve, identifying an increased-risk pregnancy earlier can provide more time for genetic counseling, additional testing, specialist support, and preparation.
Unity Fetal Risk™ Screen, available as early as 9 weeks, combines carrier screening plus cfDNA-based fetal risk for recessive and X-linked conditions to provide pregnancy-specific insights.
If You Missed It: Unity Confirm Provider Roundtable
A high-risk prenatal screening result can raise important questions for patients and providers about what comes next.
In our recent provider roundtable, a multidisciplinary panel of prenatal care providers shared real-world perspectives on patient counseling, clinical decision-making, and where Unity Confirm* may fit alongside existing standards of care. The discussion also covered practical experiences incorporating Unity Confirm into clinical workflows and supporting patients as they navigate their next steps.
Listen In: The Green Room, a Podcast from Obstetrics & Gynecology
Tune in to the latest Obstetrics & Gynecology podcast episode, featuring Dr. Eliza R. McElwee discussing her prospective, multi-site study evaluating the performance of cell-free DNA testing for recessive conditions in a large, general-risk pregnancy population.
The conversation explores emerging research and practical considerations for using cfDNA-based screening to provide pregnancy-specific fetal risk information earlier in care.
Unity is Now Available Through Epic Aura
BillionToOne’s prenatal testing portfolio is now integrated with Epic Aura, making it easier to bring Unity into your existing clinical workflow. Providers can order Unity Complete® directly within Epic, with discrete results flowing back into the patient’s electronic health record.
What to Know: Patient Outreach from Unity
The Unity team may periodically reach out to patients for routine quality and outcome follow-up, as well as opportunities to participate in research and other programs. We want to keep you informed about when and why your patients may hear directly from us. Please reach out to our research team if you have any questions about our patient outreach.
Join us as we bring the new standard of prenatal screening to life.
*Unity Confirm is not available for high-risk monosomy X pregnancies, twin or higher multiple pregnancies, vanishing twins, gestational carriers or egg donors, or for pregnancies >15 weeks 6 days gestation. Only available in the US.
Unity tests can produce false-positive and false-negative results. Results are not a guarantee. Amniocentesis should always be considered with high risk results. Important medical decisions should not rely on Unity test results alone. Clinical correlation is necessary, including but not limited to the results of prior and further prenatal testing. Unity tests are laboratory-developed tests performed in a CLIA-certified and CAP-accredited laboratory. They are not FDA-approved or FDA-cleared diagnostic tests. Test performance may vary based on gestational age and other factors.